US 11,986,484 B2
17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors
Mara Gerloni, San Diego, CA (US)
Assigned to COSMO TECHNOLOGIES LIMITED, Dublin (IE)
Filed by COSMO TECHNOLOGIES LTD., Dublin (IE)
Filed on Dec. 19, 2022, as Appl. No. 18/068,346.
Application 16/199,015 is a division of application No. 15/517,653, granted, now 10,183,030, issued on Jan. 22, 2019, previously published as PCT/EP2015/073172, filed on Oct. 7, 2015.
Application 18/068,346 is a continuation of application No. 17/223,776, filed on Apr. 6, 2021.
Application 17/223,776 is a continuation of application No. 16/820,407, filed on Mar. 16, 2020, granted, now 10,993,949, issued on May 4, 2021.
Application 16/820,407 is a continuation of application No. 16/199,015, filed on Nov. 23, 2018, granted, now 10,646,497, issued on May 12, 2020.
Claims priority of application No. 14188063 (EP), filed on Oct. 8, 2014.
Prior Publication US 2023/0128438 A1, Apr. 27, 2023
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C07J 5/00 (2006.01)
CPC A61K 31/573 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01); C07J 5/0053 (2013.01)] 3 Claims
 
1. A method of treating a tumor disease in a subject in need thereof, comprising treating said subject with a therapeutically effective amount of a compound of formula:

OG Complex Work Unit Chemistry
wherein the tumor disease is prostate carcinoma, lung carcinoma, kidney cancer, thyroid carcinoma, uterine carcinoma, or adrenal carcinoma; and wherein the prostate carcinoma is resistant to anti-androgen targeted therapy.